Two CTCL Trails on Partial Hold After Patient Death
source: shutterstock.com

Two CTCL Trails on Partial Hold After Patient Death

  The two trials evaluating lacutamab, an investigational therapy developed to treat T-cell lymphomas, were put on partial hold by the FDA. The patient died of hemophagocytic lymphohistiocytosis, which is…

Continue Reading Two CTCL Trails on Partial Hold After Patient Death

Cutaneous T Cell Lymphoma Outcomes Improved with Investigative BV Therapy in Phase 3 Clinical Trial

A study recently published in the journal Blood Advances has demonstrated that brentuximab vedotin (BV) treatment leads to improved outcomes for primary cutaneous anapestic large-cell lymphoma (C-ALCL) and CD30-expressing mycosis fungoides (MF)…

Continue Reading Cutaneous T Cell Lymphoma Outcomes Improved with Investigative BV Therapy in Phase 3 Clinical Trial